Literature DB >> 11453693

Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem.

L Pernot1, F Frénois, T Rybkine, G L'Hermite, S Petrella, J Delettré, V Jarlier, E Collatz, W Sougakoff.   

Abstract

The therapeutic problems posed by class D beta-lactamases, a family of serine enzymes that hydrolyse beta-lactam antibiotics following an acylation-deacylation mechanism, are increased by the very low level of sensitivity of these enzymes to beta-lactamase inhibitors. To gain structural and mechanistic insights to aid the design of new inhibitors, we have determined the crystal structure of OXA-13 from Pseudomonas aeruginosa in the apo form and in complex with the carbapenem meropenem. The native form consisted of a dimer displaying an overall organisation similar to that found in the closely related enzyme OXA-10. In the acyl-enzyme complex, the positioning of the antibiotic appeared to be ensured mainly by (i) the covalent acyl bond and (ii) a strong salt-bridge involving the carboxylate moiety of the drug. Comparison of the structures of OXA-13 in the apo form and in complex with meropenem revealed an unsuspected flexibility in the region of the essential serine 115 residue, with possible consequences for the catalytic properties of the enzyme. In the apo form, the Ser115 side-chain is oriented outside the active site, whereas the general base Lys70 adopts a conformation that seems to be incompatible with the activation of the catalytic water molecule required for the deacylation step. In the OXA-13:meropenem complex, a 3.5 A movement of the backbone of the 114-116 loop towards the side-chain of Lys70 was observed, which seems to be driven by a displacement of the neighbouring 91-104 loop and which results in the repositioning of the side-chain hydroxyl group of Ser115 toward the catalytic centre. Concomitantly, the side-chain of Lys70 is forced to curve in the direction of the deacylating water molecule, which is then strongly bound and activated by this residue. However, a distance of ca 5 A separates the catalytic water molecule from the acyl carbonyl group of meropenem, a structural feature that accounts for the inhibition of OXA-13 by this drug. Finally, the low level of penicillinase activity revealed by the kinetic analysis of OXA-13 could be related to the specific presence in position 73 of a serine residue located close to the general base Lys70, which results in a decrease of the number of hydrogen-bonding interactions stabilising the catalytic water molecule. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453693     DOI: 10.1006/jmbi.2001.4805

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  35 in total

1.  Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens.

Authors:  Vlatko Stojanoski; Dar-Chone Chow; Bartlomiej Fryszczyn; Liya Hu; Patrice Nordmann; Laurent Poirel; Banumathi Sankaran; B V Venkataram Prasad; Timothy Palzkill
Journal:  Biochemistry       Date:  2015-05-14       Impact factor: 3.162

2.  Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from Acinetobacter baumannii.

Authors:  Vidhu Verma; Sebastian A Testero; Kaveh Amini; William Wei; Jerome Liu; Naresh Balachandran; Tharseekan Monoharan; Siobhan Stynes; Lakshmi P Kotra; Dasantila Golemi-Kotra
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

3.  Structural Basis for Enhancement of Carbapenemase Activity in the OXA-51 Family of Class D β-Lactamases.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Nichole K Stewart; Hilary Frase; Marta Toth; Katherine A Kantardjieff; Sergei Vakulenko
Journal:  ACS Chem Biol       Date:  2015-06-12       Impact factor: 5.100

4.  Site-saturation mutagenesis of position V117 in OXA-1 β-lactamase: effect of side chain polarity on enzyme carboxylation and substrate turnover.

Authors:  Jennifer S Buchman; Kyle D Schneider; Aaron R Lloyd; Stephanie L Pavlish; David A Leonard
Journal:  Biochemistry       Date:  2012-03-28       Impact factor: 3.162

5.  Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Nichole K Stewart; Marta Toth; Malika Kumarasiri; Mayland Chang; Shahriar Mobashery; Sergei B Vakulenko
Journal:  Chem Biol       Date:  2013-09-05

6.  Clinical Variants of the Native Class D β-Lactamase of Acinetobacter baumannii Pose an Emerging Threat through Increased Hydrolytic Activity against Carbapenems.

Authors:  Emma C Schroder; Zachary L Klamer; Aysegul Saral; Kyle A Sugg; Cynthia M June; Troy Wymore; Agnieszka Szarecka; David A Leonard
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Crystal structure of carbapenemase OXA-58 from Acinetobacter baumannii.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Marta Toth; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  Molecular and biochemical characterization of OXA-45, an extended-spectrum class 2d' beta-lactamase in Pseudomonas aeruginosa.

Authors:  Mark A Toleman; Kenneth Rolston; Ronald N Jones; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Authors:  Michiyosi Nukaga; Christopher R Bethel; Jodi M Thomson; Andrea M Hujer; Anne Distler; Vernon E Anderson; James R Knox; Robert A Bonomo
Journal:  J Am Chem Soc       Date:  2008-08-30       Impact factor: 15.419

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.